Valuation: Apogee Therapeutics, Inc.

Market Cap 10.05B 8.78B 8.12B 7.45B 14.11B 968B 14.35B 96.88B 38.06B 473B 37.74B 36.91B 1,633B P/E 2026 *
-31.1x
P/E 2027 * -24x
Enterprise Value 9.07B 7.93B 7.33B 6.73B 12.73B 874B 12.95B 87.43B 34.35B 427B 34.06B 33.31B 1,473B EV / Sales 2026 *
998x
EV / Sales 2027 * 745x
Free-Float
94.47%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Apogee Therapeutics, Inc.

1 day-0.16%
1 week+0.38%
Current month+1.02%
1 month+57.30%
3 months+48.07%
6 months+66.00%
Current year+77.64%
1 week 133.54
Extreme 133.54
134.32
1 month 87.4
Extreme 87.4
134.32
Current year 60.35
Extreme 60.35
134.32
1 year 34.34
Extreme 34.34
134.32
3 years 14.19
Extreme 14.19
134.32
5 years 14.19
Extreme 14.19
134.32
10 years 14.19
Extreme 14.19
134.32
Manager TitleAgeSince
Chief Executive Officer 36 31/08/2022
Director of Finance/CFO 60 31/12/2022
Chief Tech/Sci/R&D Officer - 30/04/2023
Director TitleAgeSince
Director/Board Member 54 21/06/2023
Director/Board Member 62 31/05/2023
Director/Board Member 36 31/05/2023
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Don

Chief Executive Officer

-75,046 0.1340%
01/07/26 Fiscal year

Chief Technology Officer

13,750 0.0246%
22/06/26 Sell

Chief Technology Officer

-26,400 0.0471%
Change 5-day change 1-year change 3-year change Capi.($)
-0.16%+0.38%+249.44%+531.56% 10.05B
-0.56%-2.53%+0.21%+5.54% 49.7B
-2.85%-6.25%+366.61%+572.09% 38.09B
+1.98%+4.82%+13.71%+61.68% 35.29B
+1.78%+0.73%+32.68%-4.80% 35.13B
+0.06%+1.56%+4.41%+27.42% 27.22B
-3.27%-5.67% - - 16.14B
+1.64%+0.45%+70.86%+121.18% 15.36B
+1.06%+1.86%+15.83%+19.58% 13.89B
-1.21%+0.73%+18.02%-30.96% 13.02B
Average -0.63%-0.47%+85.75%+144.81% 25.39B
Weighted average by Cap. -0.79%-0.60%+83.18%+134.15%

Financials

2026 *2027 *
Net sales 9.09M 7.95M 7.35M 6.74M 12.76M 876M 12.98M 87.64M 34.43M 428M 34.14M 33.39M 1.48B 12.5M 10.93M 10.1M 9.27M 17.55M 1.2B 17.85M 121M 47.34M 588M 46.94M 45.91M 2.03B
Net income -318M -278M -257M -236M -446M -30.6B -454M -3.06B -1.2B -14.94B -1.19B -1.17B -51.58B -416M -364M -337M -309M -585M -40.13B -595M -4.01B -1.58B -19.6B -1.56B -1.53B -67.65B
Net Debt -980M -856M -792M -727M -1.38B -94.38B -1.4B -9.44B -3.71B -46.09B -3.68B -3.6B -159B -740M -647M -598M -549M -1.04B -71.33B -1.06B -7.14B -2.8B -34.83B -2.78B -2.72B -120B
Logo Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
Employees
261
Date Price Change Volume
16/07/26 US$134.08 -0.16% 1,359,089
15/07/26 US$134.29 +0.25% 607,392
14/07/26 US$133.96 +0.10% 1,365,160
13/07/26 US$133.82 +0.13% 1,009,120
10/07/26 US$133.65 +0.06% 787,824
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
134.08USD
Average target price
130.53USD
Spread / Average Target
-2.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APGE Stock